(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on a new research paper, “The Value of Pharmacy Benefit Management” authored by University of Chicago Professor of Economics Casey Mulligan and published today by the
(Washington D.C.) – Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s Senate Finance Committee hearing, “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare.” “PCMA commends the Senate Finance Committee
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
New report from the Congressional Budget Office highlights the value of PBMs in keeping net drug costs low for payers and patients.
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy benefit companies underscored that misguided policies targeting pharmacy benefits will lead to higher prescription drug
Court Ruling Finds that ERISA Preempts State PBM Law COURT REJECTS BID TO PREEMPT ERISA…In a unanimous decision, the U.S. Court of Appeals for the Tenth Circuit in PCMA v. Mulready court sustained PCMA’s challenge to four provisions in
(Washington, D.C.) — As the House Committee on Oversight and Reform continues its investigation into drug manufacturers’ pricing strategies, the Pharmaceutical Care Management Association (PCMA) is releasing new data on the impact of blocking competition for top-selling medications. Brand-name drug manufacturers
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released the following statement on the Congressional Budget Office’s (CBO) estimate that The INSULIN Act will increase taxpayer spending by approximately $23 billion over 10 years. Pharmacy benefit managers, PBMs,
(Washington, D.C.) — A highly consolidated insulin market limits competition and allows dramatic price increases on new and existing brand-name products, according to a new Visante analysis: “Insulins: Managing Costs with Increasing Manufacturer Prices.” The Visante analysis finds that insulin list prices escalated
The insulin market today is not the market of five years ago. The insulin market of the 2010s was defined by just three drug companies and their brand name products. The lack of competitors meant skyrocketing list prices, increasing once
©2024 PCMA. All Rights Reserved.
